MedTrace Logo

A Clinical Trial to Evaluate the Effect of Food on the Pharmacokinetics of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subjects

NCT07508462 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-04-02

No results posted yet for this study

Summary

This study is a single-dose, randomized, open-label, three-sequence, three-period crossover clinical trial to evaluate the effect of high-fat and low-fat meals on the pharmacokinetics of ammoxetine hydrochloride enteric-coated tablets in healthy subjects.

Conditions

  • Healthy Participants

Interventions

DRUG

Ammoxetine hydrochloride enteric-coated tablets

Single-dose of 60 mg of ammoxetine hydrochloride enteric-coated tablets

DRUG

Ammoxetine hydrochloride enteric-coated tablets

Single-dose of 60 mg of ammoxetine hydrochloride enteric-coated tablets

DRUG

Ammoxetine hydrochloride enteric-coated tablets

Single-dose of 60 mg of ammoxetine hydrochloride enteric-coated tablets

Sponsors & Collaborators

  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-30
Primary Completion
2024-06-17
Completion
2024-08-02

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07508462 on ClinicalTrials.gov